How Novartis AG Makes Money

Novartis AG generates 100% of its $54.5 billion FY2025 revenue from the sale of patented innovative medicines, a business model that relies entirely on scientific differentiation, clinical trial success, and the temporary monopolies granted by global patent offices. Following the complete spin-off of the Sandoz generics division in October 2023, the company abandoned the high-volume, low-margin business of manufacturing commodity drugs, choosing instead to concentrate all capital allocation on high-risk, high-reward specialty therapeutics. The financial mechanics of this model are exceptionally lucrative when successful: the company operates with a 42.2% core operating income margin, meaning that for every dollar of net sales, approximately 42 cents flows directly to the bottom line as operating profit. This margin structure is vastly superior to the 15-20% margins typical of generic manufacturers, but it requires massive upfront capital deployment. Novartis invested $10.8 billion in research and development during FY2025, a figure that represents approximately 19% of total revenue, funding a pipeline of over 200 clinical projects across oncology, immunology, cardiovascular, and neuroscience. The revenue streams are heavily concentrated in a few massive blockbuster franchises. Oncology is the largest therapeutic area, driven by Kisqali ($4.7 billion in FY2025 sales) for breast cancer, Pluvicto ($2.0 billion) for prostate cancer, and Scemblix for chronic myeloid leukemia. Immunology is the second pillar, anchored by Cosentyx ($6.6 billion) for psoriasis and ankylosing spondylitis, and Kesimpta ($4.4 billion) for multiple sclerosis. The cardiovascular franchise, historically dominated by Entresto ($7.7 billion), is currently undergoing a painful transition as the drug faces generic competition in the US, a reality that caused Entresto sales to drop 43% in Q4 2025 alone. To mitigate these patent cliff risks, the business model incorporates aggressive inorganic growth. The company utilizes its $17.5 billion annual free cash flow to acquire clinical-stage biotechnology companies that have already de-risked their lead assets through Phase II trials. The $2.9 billion acquisition of MorphoSys in 2024 brought the anti-myelofibrosis drug pelabresib into the portfolio, while the $3.5 billion purchase of Chinook Therapeutics in 2023 secured late-stage assets for rare kidney diseases like IgA nephropathy. This bolt-on acquisition strategy is designed to fill the revenue gaps left by patent expirations without relying solely on internal discovery. The pricing power inherent in the innovative pharma model allows Novartis to charge premium prices in the US market, which accounts for approximately 45% of total global sales. However, this pricing power is increasingly constrained by the US Inflation Reduction Act, which allows Medicare to negotiate drug prices. Entresto was explicitly named in recent Medicare negotiation rounds, forcing Novartis to accept lower reimbursement rates or risk exclusion from the federal program. The company's response has been to shift its focus toward rare diseases and oncology, therapeutic areas where patient populations are smaller, clinical outcomes are more dramatic, and pricing pressure is less severe. The commercial infrastructure required to support this model is highly specialized. Novartis employs a sales force of thousands of highly trained scientific liaisons who engage directly with oncologists, cardiologists, and immunologists, providing complex clinical data rather than simple product pitches. This high-touch commercial model is incredibly expensive to maintain, requiring significant selling, general, and administrative (SG&A) expenditures, but it is necessary to drive the adoption of complex therapies like radioligands, which require specialized handling and administration at certified medical centers. The ultimate goal of the business model is to achieve a sustainable compound annual growth rate (CAGR) of 5-6% at constant currency through 2030, a target that requires the successful launch of at least eight new molecular entities currently in the late-stage pipeline. If the company fails to launch these assets successfully, the high fixed-cost structure of the R&D and commercial infrastructure will rapidly erode the 42% operating margin, exposing the fundamental vulnerability of a pure-play innovative pharma model: it is only as valuable as its next patent. The supply chain for the company's radioligand therapies represents a unique logistical challenge that further defines its business model. Unlike small molecule pills that can be manufactured in massive batches and stored in warehouses for years, radioligands like Pluvicto utilize the radioactive isotope Lutetium-177, which has a physical half-life of just 6.7 days. This means the drug must be manufactured, quality-tested, shipped, and administered to the patient within a matter of days, requiring a highly decentralized, just-in-time global supply chain. Novartis has invested hundreds of millions of dollars to build a network of specialized nuclear pharmacies and certified treatment centers capable of handling radioactive materials, creating a massive barrier to entry for competitors who would need to replicate this infrastructure from scratch. This logistical moat is complemented by the clinical data package surrounding Pluvicto, which demonstrated a 4.5-month improvement in overall survival in the VISION Phase III trial, a statistically significant and clinically meaningful endpoint that has cemented the drug's position as a standard of care in late-line prostate cancer. The business model also relies heavily on lifecycle management to extend the commercial viability of its key assets. For Cosentyx, the company has continuously expanded the label to include new indications such as non-radiographic axial spondyloarthritis and enthesitis-related arthritis, while also launching higher-concentration, single-use autoinjectors to improve patient compliance and convenience. This strategy of continuous clinical and formulation innovation allows Novartis to defend its market share against biosimilar competition, which typically enters the market 6 to 12 months after the primary patent expiration. The financial discipline required to maintain this complex business model is evident in the company's strict capital allocation framework, which prioritizes R&D investment and targeted acquisitions over large-scale, transformational mergers. The company has consistently returned over 50% of its free cash flow to shareholders through a progressive dividend policy and an aggressive share buyback program, a strategy that has supported the stock price during the transition period between legacy patent cliffs and new product launches. The FY2025 financial results demonstrate that this disciplined approach to capital allocation is generating significant value, as the company has been able to fund its $10.8 billion R&D budget, execute over $6 billion in strategic acquisitions, and return over $10 billion to shareholders, all while maintaining a fortress-like balance sheet with substantial cash reserves and manageable debt levels. The success of the Novartis business model ultimately depends on its ability to continuously identify and commercialize novel biological targets that address significant unmet medical needs, a capability that is rooted in the company's deep scientific heritage and its extensive network of academic partnerships. The company's Novartis Institutes for BioMedical Research (NIBR) operates research centers in Cambridge, Massachusetts, Basel, Shanghai, and Emeryville, focusing on cutting-edge areas such as gene therapy, RNA interference, and targeted protein degradation. By maintaining a strong internal discovery engine while simultaneously scouting external innovation through its venture capital arm, Novartis Ventures, the company ensures a steady flow of early-stage assets that can be advanced through its global clinical development infrastructure. This dual approach to innovation, combining internal scientific excellence with external capital deployment, is the engine that drives the Novartis business model and positions the company to deliver sustained long-term growth in the highly competitive global pharmaceutical market.

Novartis AG's growth strategy is built on three specific, named initiatives with clear financial targets: the acceleration of radioligand therapy launches, the aggressive expansion of the rare disease portfolio through bolt-on acquisitions, and the lifecycle management of key immunology franchises. The company has committed to launching at least eight new molecular entities or major label expansions between 2025 and 2030, a pipeline that includes potential blockbusters in oncology, immunology, and cardiovascular disease. The radioligand initiative is the cornerstone of this strategy, with the company investing heavily in manufacturing capacity and clinical trials to expand Pluvicto into earlier lines of prostate cancer and launch new FAP-targeting therapies for solid tumors. The target is to achieve over $5 billion in annual radioligand sales by 2030, a figure that would make this modality one of the company's largest therapeutic franchises. The rare disease growth strategy focuses on leveraging the Chinook Therapeutics acquisition to establish Novartis as the leader in complement-mediated diseases. The company is advancing atrasentan and other late-stage assets for IgA nephropathy, a condition affecting hundreds of thousands of patients globally with few effective treatment options. The goal is to achieve peak sales of over $3 billion for the rare disease portfolio by 2032. The immunology lifecycle management strategy aims to extend the commercial life of Cosentyx and Kesimpta by launching new indications, combination therapies, and subcutaneous delivery methods. By continuously expanding the clinical utility of these assets, Novartis can defend against biosimilar competition and maintain premium pricing in key markets. To fund these initiatives, the company maintains a disciplined capital allocation framework that prioritizes R&D investment and strategic acquisitions over large-scale, transformational mergers. The $2.9 billion acquisition of MorphoSys and the $3.5 billion purchase of Chinook Therapeutics exemplify this approach, providing the company with de-risked, late-stage assets that can be integrated into the existing commercial infrastructure to drive immediate revenue growth. The execution of this growth strategy requires a highly skilled and motivated workforce, and Novartis has invested heavily in talent acquisition and development to ensure that it has the necessary scientific and commercial expertise to succeed. The company has established a global network of research centers and commercial offices that are strategically located in key biotechnology hubs, allowing it to attract top talent from academia and industry. Novartis has also implemented a comprehensive training and development program for its employees, focusing on building the skills and capabilities required to succeed in the rapidly evolving pharmaceutical industry. The company's culture of innovation and collaboration is a key enabler of its growth strategy, fostering an environment where employees are encouraged to think creatively, take calculated risks, and work together to solve complex scientific and commercial challenges. The growth strategy also includes a strong focus on sustainability and corporate social responsibility, recognizing that the long-term success of the company is inextricably linked to the health and well-being of the communities in which it operates. Novartis has committed to achieving net zero greenhouse gas emissions across its value chain by 2040, and has implemented a comprehensive environmental, social, and governance (ESG) program that focuses on reducing its environmental footprint, promoting diversity and inclusion, and ensuring access to healthcare for underserved populations. The company's ESG initiatives are integrated into its overall business strategy, and its performance against these goals is regularly monitored and reported to stakeholders. The successful execution of Novartis's growth strategy will require the company to navigate a complex and dynamic external environment, characterized by rapid technological change, intense competition, and evolving regulatory and pricing pressures. However, the company's strong scientific heritage, robust pipeline, and disciplined capital allocation strategy provide a solid foundation for future growth, and its commitment to innovation and patient-centricity positions it well to deliver on its strategic objectives and create significant value for all stakeholders.